Scholar Rock to showcase preclinical, phase 1 clinical data of SRK-015
Category: #health  By Pankaj Singh  Date: 2019-10-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Scholar Rock to showcase preclinical, phase 1 clinical data of SRK-015

SMA is a rare genetic disease that typically affects young children. Currently, there is no cure for spinal muscular atrophy (SMA), however, various pharmaceutical firms across the world are working to discover a novel, innovative treatment for the disorder. Support and treatment is offered by various firms to help patients with the disorder to at least have the best quality of life.

Scholar Rock, a US based biopharmaceutical company headquartered in Cambridge, reportedly announced that preclinical and Phase 1 data for SRK-015 would be showcased at World Muscle Society Congress (WMSC) which is being conducted between October 1 and October 5, 2019 at Copenhagen, Denmark.

SRK is an extremely selective inhibitor used against myostatin activation. Myostatin is a negative muscle mass regulator and is presently being examined inside the TOPAZ Phase 2 clinical trial to treat patients with Type 3 and Type 2 SMA.

CEO and President of Scholar Rock, Nagesh Mahanthappa, Ph.D, stated that collectively, the Phase 1 as well as preclinical healthy volunteer data has offered the base for further advancing the SRK-015 to the company’s TOPAZ Phase 2 clinical trial.

Mahanthappa added that the company is thrilled about the potential role of SRK-015 as the first muscle-directed treatment that addresses the prolonged functional deficits that by some patients suffering with SMA experience.

Mahanthappa further stated that the company looks forward to the data from forthcoming clinical read-outs of the TOPAZ study, beginning with the primary PK/PD results by 2019 end and interim efficacy as well as interim safety and efficacy data during the first half of 2020.

The preclinical data which would be showcased at WMS shows enhanced muscle strength following the administration of muSRK-015P, the mouse analog of the SRK-015, in mouse models of late and early SMN restoration.

Treatment with muSRK-015P resulted in approximately 20%-51% growth in maximal torque, at over ≥ 40 Hz, of the subject’s plantar flexor muscle group along with a higher percentage of the muscle fibers in comparison with placebo treatment.

The phase 1 trial to be showcased at WMS shows sustained and strong target engagement, including durable saturation, following the administration of SRK-015 in both multiple-ascending and single-ascending dose portions of the study.

 

Source credit: http://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-present-preclinical-and-phase-1-clinical-data-srk

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
By Pankaj Singh

A clinical stage biotechnology company, PDC*line Pharma, focused upon developing a new class of effective and scalable active immunotherapies for treating cancers, recently announced completion of a Series B round of funding. The company ha...

VMware plans to acquire Nyansa to expand its SW-WAN portfolio
VMware plans to acquire Nyansa to expand its SW-WAN portfolio
By Pankaj Singh

  The deal for the acquisition will close in the first quarter of the FY2021 The terms of the deal have not been disclosed by the company yet VMware, a leading provider of virtualization and cloud computing software and services, recently ...

Rogers Communications launches 5G network services across Canada
Rogers Communications launches 5G network services across Canada
By Pankaj Singh

  The network will first be implemented in Toronto, Vancouver, Montreal and Ottawa Rogers has collaborated with Ericsson to provide the required technology to develop the network Rogers Communications – a Toronto based telecommunicat...